{"id":177288,"date":"2022-05-27T10:23:25","date_gmt":"2022-05-27T02:23:25","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=177288"},"modified":"2022-05-27T10:23:25","modified_gmt":"2022-05-27T02:23:25","slug":"adagene-announces-publication-at-asco-of-interim-monotherapy-dose-escalation-data-showing-compelling-safety-profile-of-anti-ctla-4-safebody-adg126-with-repeat-dosing-across-dose-levels","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=177288","title":{"rendered":"Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody\u00ae ADG126, with Repeat Dosing Across Dose Levels"},"content":{"rendered":"\n<p><strong>SAN DIEGO and SUZHOU, China, May 27 (Bernama-GLOBE NEWSWIRE) &#8212;<\/strong>&nbsp;Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the potential best-in-class safety profile of its anti-CTLA-4 monoclonal antibody (mAb), ADG126. Interim results from the Phase 1 dose escalation portion of an ongoing Phase 1b\/2 trial of ADG126 are published in an abstract on the American Society of Clinical Oncology (ASCO)&nbsp;<a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=a4SHHGq1eVso5y3GTaIqZkzdcchwRWQsG2edlmbsce8vsaS-jCekjvRINJmdbQRMu0BBSopytIULAJBjwtPgAps3ngv6XERS_oZukwlJM6w=\" rel=\"noreferrer noopener\">meeting website<\/a>&nbsp;in conjunction with the 2022 Annual Meeting taking place in Chicago from June 3-7, 2022.<\/p>\n\n\n\n<p>Key data in the abstract, titled \u201cPhase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong Treg depletion and soft ligand blocking in patients with advanced solid tumors,\u201d include the following:<\/p>\n\n\n\n<p><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=43263\" data-type=\"URL\" data-id=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=43263\">http:\/\/mrem.bernama.com\/viewsm.php?idm=43263<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and SUZHOU, China, May 27 (Bernama-GLOBE NEWSWIRE) &#8212;&nbsp;Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the potential best-in-class safety profile of its anti-CTLA-4 monoclonal antibody (mAb), ADG126. Interim results from the Phase 1 dose escalation portion of an [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/177288"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=177288"}],"version-history":[{"count":1,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/177288\/revisions"}],"predecessor-version":[{"id":177289,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/177288\/revisions\/177289"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=177288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=177288"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=177288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}